|
JPH0328966Y2
(enExample)
|
1987-10-16 |
1991-06-20 |
|
|
|
WO1992019973A1
(en)
|
1991-04-26 |
1992-11-12 |
Surface Active Limited |
Novel antibodies, and methods for their use
|
|
AU6235294A
(en)
|
1993-02-02 |
1994-08-29 |
Scripps Research Institute, The |
Methods for producing polypeptide binding sites
|
|
US5981478A
(en)
|
1993-11-24 |
1999-11-09 |
La Jolla Cancer Research Foundation |
Integrin-binding peptides
|
|
WO2000047602A1
(en)
|
1999-02-10 |
2000-08-17 |
Human Genome Sciences, Inc. |
33 human secreted proteins
|
|
JP4332581B2
(ja)
|
1998-02-19 |
2009-09-16 |
旭化成株式会社 |
ヒトデルタ−３
|
|
JP4139508B2
(ja)
|
1998-02-19 |
2008-08-27 |
旭化成株式会社 |
ヒトデルター３
|
|
US6344443B1
(en)
|
1998-07-08 |
2002-02-05 |
University Of South Florida |
Peptide antagonists of tumor necrosis factor alpha
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
JP2003507029A
(ja)
|
1999-08-19 |
2003-02-25 |
カイロン コーポレイション |
Ｎｏｔｃｈレセプターリガンドおよびその使用
|
|
US6436703B1
(en)
|
2000-03-31 |
2002-08-20 |
Hyseq, Inc. |
Nucleic acids and polypeptides
|
|
DK1272647T3
(en)
|
2000-04-11 |
2014-12-15 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
|
WO2002014358A2
(en)
|
2000-08-11 |
2002-02-21 |
Eli Lilly And Company |
Novel secreted proteins and their uses
|
|
EP1293514B1
(en)
|
2001-09-14 |
2006-11-29 |
Affimed Therapeutics AG |
Multimeric single chain tandem Fv-antibodies
|
|
EP1434881A4
(en)
|
2001-09-17 |
2005-10-26 |
Protein Design Labs Inc |
METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
|
|
AU2003295328A1
(en)
|
2002-10-02 |
2004-04-23 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20040115204A1
(en)
|
2002-12-11 |
2004-06-17 |
Fanger Gary R. |
Antibodies to treat cancer
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
DK1709081T3
(da)
|
2004-01-16 |
2011-06-06 |
Regeneron Pharma |
Fusionspolypeptider, der kan aktivere receptorer
|
|
US20050175619A1
(en)
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
|
BRPI0510674A
(pt)
|
2004-07-15 |
2007-12-26 |
Xencor Inc |
variantes fc otimizadas
|
|
WO2006036834A2
(en)
|
2004-09-24 |
2006-04-06 |
Amgen Inc. |
MODIFIED Fc MOLECULES
|
|
WO2006047340A2
(en)
|
2004-10-22 |
2006-05-04 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
|
CN101123983A
(zh)
|
2004-10-27 |
2008-02-13 |
米迪缪尼股份有限公司 |
特定修饰对相关抗原的亲和力来调节抗体的特异性
|
|
US20060121042A1
(en)
|
2004-10-27 |
2006-06-08 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
AU2006204459B2
(en)
|
2005-01-05 |
2012-11-01 |
F-Star Therapeutics Limited |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
CA2596248A1
(en)
|
2005-01-31 |
2006-08-10 |
Vaxinnate Corporation |
Method to identify polypeptide toll-like receptor (tlr) ligands
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
|
JP2009523709A
(ja)
|
2005-12-16 |
2009-06-25 |
ジェネンテック・インコーポレーテッド |
神経膠腫の診断、予後の予測及び治療の方法
|
|
WO2007080597A2
(en)
|
2006-01-16 |
2007-07-19 |
Compugen Ltd. |
Polynucleotide and polypeptide sequences and methods for diagnosis
|
|
CN101466733A
(zh)
|
2006-04-14 |
2009-06-24 |
特鲁比昂药品公司 |
包含免疫球蛋白铰链区和Fc效应子功能改变了的Fc区的结合蛋白
|
|
WO2007134327A2
(en)
|
2006-05-15 |
2007-11-22 |
Sea Lane Biotechnologies, Llc. |
Neutralizing antibodies to influenza viruses
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
US20100061933A1
(en)
|
2006-10-20 |
2010-03-11 |
Naoki Kimura |
Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
|
|
PT2155783E
(pt)
|
2007-04-03 |
2013-11-07 |
Amgen Res Munich Gmbh |
Domínio de ligação específico inter-espécies
|
|
KR101589759B1
(ko)
|
2007-04-03 |
2016-01-29 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 ｃｄ３―입실론 결합 도메인
|
|
MX2009013816A
(es)
|
2007-06-21 |
2010-02-24 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos.
|
|
EP3492488A1
(en)
|
2007-08-22 |
2019-06-05 |
The Regents of The University of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
JP5889533B2
(ja)
|
2008-01-31 |
2016-03-22 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
改変された抗体定常ドメイン分子
|
|
WO2009124931A2
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Amino acid sequences directed against the notch pathways and uses thereof
|
|
ES2628108T3
(es)
|
2008-09-03 |
2017-08-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos multiespecíficos
|
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
|
CN102369021B
(zh)
|
2008-12-19 |
2016-09-07 |
宏观基因有限公司 |
共价双抗体及其用途
|
|
DK3342786T3
(en)
|
2010-01-29 |
2021-09-27 |
Chugai Pharmaceutical Co Ltd |
Anti-dll3-antistof
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
WO2011127350A1
(en)
|
2010-04-09 |
2011-10-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
DK2560683T4
(da)
|
2010-04-23 |
2022-08-29 |
Hoffmann La Roche |
Fremstilling af heteromultimeriske proteiner
|
|
RU2604490C2
(ru)
|
2010-11-05 |
2016-12-10 |
Займворкс Инк. |
ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
|
|
CN103328514B
(zh)
|
2010-11-09 |
2015-12-02 |
阿尔蒂单抗治疗公司 |
用于抗原结合的蛋白复合物及其使用方法
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
CA2824389A1
(en)
|
2011-01-10 |
2012-07-19 |
Emory University |
Antibodies directed against influenza
|
|
JP2014514314A
(ja)
|
2011-04-20 |
2014-06-19 |
ゲンマブ エー／エス |
Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
|
|
ME03440B
(me)
|
2011-05-21 |
2020-01-20 |
Macrogenics Inc |
Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
|
|
MX340498B
(es)
|
2011-06-30 |
2016-07-11 |
Chugai Pharmaceutical Co Ltd |
Polipeptido heterodimerizado.
|
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
PT2748201T
(pt)
|
2011-08-23 |
2018-02-08 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas que ativam as células t
|
|
ES2971444T3
(es)
|
2011-10-11 |
2024-06-05 |
F Hoffmann Lar Roche Ag |
Ensamblaje mejorado de anticuerpos biespecíficos
|
|
WO2013059593A1
(en)
|
2011-10-20 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
|
US20150166654A1
(en)
|
2012-05-30 |
2015-06-18 |
Chugai Seiyaku Kabushiki Kaisha |
Target tissue-specific antigen-binding molecule
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
MX389442B
(es)
|
2013-11-11 |
2025-03-20 |
Chugai Pharmaceutical Co Ltd |
Región variable de anticuerpo modificada que contiene molécula de unión al antígeno.
|
|
EA201691683A1
(ru)
|
2014-02-21 |
2017-04-28 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
|
|
EP3129407A2
(en)
|
2014-03-12 |
2017-02-15 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
JPWO2015146438A1
(ja)
|
2014-03-26 |
2017-04-13 |
国立大学法人東北大学 |
ヒト上皮増殖因子受容体を標的とした二重特異性抗体
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
AR101400A1
(es)
|
2014-07-31 |
2016-12-14 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
|
|
CA2956471C
(en)
|
2014-07-31 |
2024-09-10 |
Amgen Res Munich Gmbh |
OPTIMIZED CONSTRUCTIONS OF SINGLE-CATENAL, BI-SPECIFIC, AND CROSS-SPECIFIC ANTIBODY
|
|
EP2982692A1
(en)
*
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
AU2015314826A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
WO2016076345A1
(ja)
|
2014-11-11 |
2016-05-19 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子のライブラリ
|
|
JP6826529B2
(ja)
|
2015-06-05 |
2021-02-03 |
中外製薬株式会社 |
免疫活性化剤の併用
|
|
EP3345928B1
(en)
|
2015-07-10 |
2020-06-24 |
Merus N.V. |
Human cd3 binding antibody
|
|
TWI793062B
(zh)
*
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
コントースボディ−単鎖標的結合物質
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
JP7247091B2
(ja)
|
2016-12-20 |
2023-03-28 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
|
|
SG11201909547TA
(en)
|
2017-05-05 |
2019-11-28 |
Amgen Inc |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
|
TW201938194A
(zh)
|
2017-12-05 |
2019-10-01 |
日商中外製藥股份有限公司 |
包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
|
|
WO2019131988A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
TWI848953B
(zh)
*
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
BR112021001693A2
(pt)
|
2018-08-03 |
2021-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno contendo dois domínios de ligação ao antígeno q ligados entre si
|
|
SG11202101912UA
(en)
|
2018-09-28 |
2021-04-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
|
|
SG11202102882YA
(en)
|
2018-09-28 |
2021-04-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule comprising altered antibody variable region
|
|
CA3115089A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
EP4100433A4
(en)
|
2020-02-05 |
2024-03-13 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES
|
|
EP4126970A4
(en)
|
2020-03-31 |
2024-05-01 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing multispecific antigen-binding molecules
|
|
PH12022500013A1
(en)
|
2020-03-31 |
2023-09-11 |
Chugai Pharmaceutical Co Ltd |
Dll3-targeting multispecific antigen-binding molecules and uses thereof
|